• In April 2026, Krystal Biotech announced that the U.S. FDA had granted Regenerative Medicine Advanced Therapy designation to KB707, its redosable HSV-based immunotherapy for advanced or metastatic non-small cell lung cancer, following encouraging early clinical data.
• This RMAT status gives KB707 enhanced FDA guidance and potential rolling review, elevating the profile of Krystal’s emerging oncology franchise within its broader genetic medicines platform.
• We’ll now examine how RMAT status for KB707 could influence Krystal Biotech’s investment narrative, particularly its evolving oncology pipeline profile.

The latest GPUs need a type of rare earth metal called Terbium and there are only 31 companies in the world exploring or producing it. Find the list for free.

Krystal Biotech Investment Narrative Recap

To own Krystal Biotech, you need to believe its HSV-1 platform can extend beyond VYJUVEK into meaningful new franchises, with oncology as an important test case. In the near term, the most important catalyst still centers on continued commercial execution for VYJUVEK, while the key risk remains revenue volatility and product concentration. The new RMAT status for KB707 highlights longer term optionality in cancer, but does not materially change those core, near term drivers.

What does feel directly connected is Krystal’s plan to showcase KB707 and other programs at major 2026 conferences like ASCO and ASGCT, where more detailed NSCLC data and scientific context could shape how investors weigh the RMAT designation against existing risks. Those presentations, alongside updates in cystic fibrosis and respiratory gene therapy, may influence how much value investors ascribe to Krystal’s broader pipeline beyond VYJUVEK.

Yet while RMAT status broadens the story, investors should still pay close attention to the risk that VYJUVEK’s concentrated revenue base and quarter to quarter “waviness” could...

Krystal Biotech's narrative projects $987.9 million revenue and $571.3 million earnings by 2029.

Uncover how Krystal Biotech's forecasts yield a $315.00 fair value, a 18% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already modeling revenues near US$1.4 billion and earnings around US$947.2 million by 2029, so if you worry about pipeline delays and diversification risk, it is worth comparing how this new KB707 RMAT milestone might change those bullish assumptions and where your own view fits along that wide spectrum of expectations.

Explore 6 other fair value estimates on Krystal Biotech - why the stock might be worth over 2x more than the current price!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Krystal Biotech research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free Krystal Biotech research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Krystal Biotech's overall financial health at a glance.

Looking For Alternative Opportunities?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• Find 50 companies with promising cash flow potential yet trading below their fair value.
• We've uncovered the 13 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Invest in the nuclear renaissance through our list of 91 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.